Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.: history, ownership, mission, how it works & makes money

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd., founded in 2002 and restructured into a joint-stock company in 2013 before listing on the Shenzhen Stock Exchange as 300357 on January 21, 2014, has built a vertically integrated allergen-diagnosis-and-treatment business that reported annual revenue of 925.39 million CNY in 2024 (up 9.10% year-on-year), employs 1,679 staff, and pursues a mission to improve allergy care through innovation and patient-centric values; with a registered capital of 523.584 million CNY and a market capitalization of 17.06 billion CNY as of November 7, 2025 (a 39.45% one-year increase), the company allocates about 10% of revenue to R&D focused on biologics and monoclonal antibodies, manufactures under GMP with ISO 9001 and FDA-recognized credentials, monetizes patented products such as Changdi (dust mite drops), Changhao (artemisia annua pollen sublingual drops), Changdian and Changdian II diagnostic kits, leverages strategic domestic and international partnerships and educational outreach, and-after reporting these results-projected a first-half-2025 net profit attributable to shareholders of 170-185 million CNY (a year-on-year increase of 13.92%-23.97%), while aiming for ~22% annual earnings growth and expansion into biosimilars to strengthen its market position

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (300357.SZ): Intro

• Founded: 2002 - focused on allergic disease diagnostics and therapeutics.
• Corporate restructuring: Converted to a joint-stock company in 2013 to strengthen capital structure and operational flexibility.
• Listing: Shenzhen Stock Exchange (ticker 300357) - IPO dated January 21, 2014.
• Employees: 1,679 as of December 31, 2024.

• R&D-led product pipeline: develops reagents and diagnostic kits for allergic diseases, investing in product development to expand clinical adoption.
• Manufacturing and sales: revenue comes from commercial sales of diagnostic kits, immunotherapy products and related reagents to hospitals, clinics and distributors.
• Market promotion: increased marketing and channel development for core products has driven recent revenue growth and the projected profit uplift in H1 2025.
• Listed equity structure: as a public joint-stock company (300357.SZ), the company accesses capital markets for growth financing and shareholder value creation.

• 2002 - Company established with an allergy-disease focus.
• 2013 - Converted to joint-stock company, improving governance and capital access.
• 2014-01-21 - Listed on Shenzhen Stock Exchange (300357.SZ).
• 2024 - Reported revenue of 925.39 million CNY; workforce 1,679.
• 2025-07 - Projected H1 net profit 170-185 million CNY (YoY +13.92% to +23.97%).

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (300357.SZ): History

• Founded and early R&D focus: biologics and small-molecule drugs for oncology and metabolic diseases.
• Expansion: built GMP production capacity and added contract development and manufacturing (CDMO) services.
• Public listing: boosted capital access and investor base, enabling accelerated pipeline development and manufacturing scale-up.

• Public listing on Shenzhen Stock Exchange - diverse base of institutional and individual investors.
• Institutional investors and funds hold significant blocks, supporting liquidity and governance oversight.
• Management and key insiders retain strategic stakes aligned with long-term development.

• Develop safe, effective medicines and scalable manufacturing solutions to address unmet medical needs.
• Combine R&D innovation with reliable production to bring therapies to market efficiently.

• Product sales - revenues from proprietary pharmaceuticals marketed domestically and in select export markets.
• CDMO services - contract manufacturing and development for external biotech and pharmaceutical customers.
• Licensing & collaborations - milestone and royalty income from out-licensing or joint development agreements.
• R&D-driven pipeline value - investor valuation reflects expected future cash flows from pipeline commercialization.

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (300357.SZ): Ownership Structure

• Mission: Improve diagnosis and treatment of allergic diseases to reduce patient burden.
• Innovation: Develop advanced biopharmaceutical technologies for allergen detection and treatment products.
• Integrity: Operate transparently to build trust with patients, regulators and partners.
• Patient-centricity: Prioritize patient well-being and satisfaction in product design and services.
• Respect: Foster a culture that values employees, partners and customers.

• R&D-driven product pipeline: revenue from proprietary allergen detection kits, immunotherapy products and reagents.
• Commercial sales: domestic hospital, clinical laboratory and distributor channels.
• Service contracts: diagnostic services and technical support for clinical partners.
• Licensing & collaborations: partnerships for technology transfer and co-development.

• Major founding/promoter shareholder: ~28% - strategic control and board influence.
• Top institutional investors (combined): ~35% - includes funds and biomedical-focused institutions.
• Retail/free float: ~37% - liquidity on ChiNext and secondary market shareholders.

• Reinvest in R&D to expand allergen immunotherapy and precision diagnostics.
• Leverage institutional investor relationships to scale manufacturing and regulatory approvals.
• Maintain compliance and transparent governance to align with integrity and patient-centric values.

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (300357.SZ): Mission and Values

• Vertically integrated model: in-house R&D, GMP manufacturing, and sales/marketing.
• Quality & compliance: GMP-compliant manufacturing, ISO 9001 certified, and holders of FDA approvals for specified facilities/products.
• R&D focus: targets advanced biologics-especially monoclonal antibodies-with ~10% of total revenue reinvested into R&D.
• Strategic collaborations: partnerships with domestic and international pharmaceutical firms for co-development, licensing and co-marketing.
• Workforce: 1,679 employees as of December 31, 2024, supporting R&D, production, quality control and commercial operations.

• Discovery & R&D: internal discovery teams and partnered research programs generate candidate biologics; ~10% of revenue funds ongoing R&D to advance candidates through preclinical and clinical stages.
• Manufacturing: GMP-certified production lines manufacture clinical and commercial biologics to internal and partner specifications; cost controls and scale efficiencies reduce per-unit cost as volumes grow.
• Regulatory & quality: ISO 9001 and FDA approvals support market access and export potential, enabling revenue from regulated markets and licensing agreements.
• Commercialization & sales: direct sales in domestic markets plus co-marketing and licensing deals internationally; revenue streams include product sales, milestone payments, licensing fees and co-development revenue.
• Partnership-driven expansion: strategic alliances accelerate development timelines and broaden geographic reach, often sharing development costs and downstream revenues.

• R&D spend as % of revenue (target ~10%) - indicates pipeline investment intensity.
• Manufacturing capacity utilization - impacts gross margins and ability to supply partners.
• Regulatory approvals and launch timelines - drive near- to mid-term revenue ramps for new biologics.
• Partnering activity and licensing milestones - can produce lump-sum inflows and recurring royalties.

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (300357.SZ): How It Works

• Primary revenue comes from sales of patented therapeutic solutions addressing common allergens: pollen, dust mites and pet dander.
• Flagship products include Changdi (dust mite sublingual drops), Changhao (artemisia annua pollen allergen sublingual drops), Changdian (dust mite skin prick diagnostic kit) and Changdian II (house dust mite skin prick diagnosis kit).
• R&D activities, clinical validation and regulatory filings support product differentiation and account for roughly 10% of total revenue in the latest fiscal year.
• Complementary activities include physician training, patient education programs to raise allergy awareness, and distribution partnerships to expand market reach and retention.

• Allergen therapeutics (dust mite sublingual drops, pollen drops): ~65% of revenue.
• Diagnostic kits (Changdian, Changdian II) and related consumables: ~15% of revenue.
• Other clinical and support services, distributor margins and exports: ~10% of revenue.
• R&D services, licensing, collaborations and grants: ~10% of revenue.

• Discovery & development: identification and standardization of allergen extracts; clinical trials and stability testing.
• Manufacturing: in-house GMP-compliant production of allergen extracts and kit components.
• Regulatory & quality: product registration, batch release and QC documentation to meet Chinese NMPA and export requirements.
• Distribution & sales: direct sales to hospitals/clinics, partnerships with specialty pharmacies and distributors for retail/subspecialty channels.
• Post-market support: physician education, patient adherence programs and follow-up to ensure multi-dose regimen continuation and brand loyalty.

• Recurring treatment model: sublingual immunotherapy programs require multiple months of dosing, creating repeat purchase streams.
• Product portfolio diversification: multiple allergen indications and diagnostic offerings reduce single-product risk.
• R&D reinvestment (~10% of revenue) funds next-generation extracts and diagnostics to expand indication coverage.
• Educational initiatives increase diagnosis rates and treatment uptake, supporting long-term demand.

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (300357.SZ): How It Makes Money

• Core revenue streams: allergy diagnostics (test kits & platforms), prescription biologics for allergy/immunology, and biosimilar product sales and licensing.
• Commercial strategy: direct sales to hospitals and clinics, distributor networks, and partnerships for overseas registration and commercialization.
• R&D and CMO income: milestone payments, licensing fees, and contract manufacturing for third parties.

• Market position & outlook: the 39.45% market-cap increase and 22% earnings growth projection reflect investor confidence and a favorable outlook as the company scales biosimilar offerings and strengthens global distribution.
• Growth drivers: biosimilar pipeline commercialization, expanded diagnostic adoption, strategic alliances, and high-quality GMP manufacturing capacity.